Skip to content

Study of absorption and elimination rate of Tofacitinib 5-mg tablets in comparison with Tofacitinib brand tablets (Xeljanz®).

Comparative bioequivalence study of the Tofacitinib 5-mg Tablets manufactured by Noavaran Daroui Kimia Company with Tofacitinib brand tablets (Xeljanz®) by Pfizer company

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200407046981N47
Enrollment
24
Registered
2022-10-31
Start date
2022-12-06
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioequivalence study.

Interventions

Intervention 1: Intervention group: In this group, volunteers are given a single oral dose of Tofacitinib 5mg tablets produced by Noavaran Daroui Kimia Co. (Domestic). In each period, 12 of 24 subject

Sponsors

Kimia pharmaceutical Co
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: The weight limit of each volunteer should be between 60 and 100 kg. All volunteers must be non-smokers. They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed. Candidates who have consented to the consent form.

Exclusion criteria

Exclusion criteria: En Known hypersensitivity or idiosyncratic reaction to Tofacitinib or any ingredients. Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg. Taking any medicine during two week before dosing. Patients with serious infection (eg, sepsis) or active infection including local infection Patients with active or latent tuberculosis, severe hepatopathy Patients with absolute neutrophil count (ANC) less than 500 cells/mm3 Patients with an absolute lymphocyte count (ALC) of less than 500 cells per cubic millimeter Patients whose hemoglobin level is less than 8 grams per deciliter Patients with nephropathy (BUN20 or creatinine>1.5)

Design outcomes

Primary

MeasureTime frame
Peak Plasma Concentration (Cmax). Timepoint: 0 (before dosing),0.25, 0.5, 0.75, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hour after dosing. Method of measurement: High-performance liquid chromatography—mass spectrometry (HPLC-MS).

Secondary

MeasureTime frame
AUC (Area Under the Concentration-Time Curve. Timepoint: 0 (before dosing), 0.25, 0.5, 0.75, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hour after dosing. Method of measurement: Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA) or SPSS.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatima Molavi

Tabriz University of Medical Sciences

Molavif@tbzmed.ac.ir+98 41 3336 2700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026